vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $66.0M, roughly 1.8× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 5.0%, a 34.4% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $9.1M).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
HIPO vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $66.0M |
| Net Profit | $6.0M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | 5.6% | 33.5% |
| Net Margin | 5.0% | 39.4% |
| Revenue YoY | 18.2% | — |
| Net Profit YoY | -86.4% | 134.0% |
| EPS (diluted) | $0.31 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.4M | — | ||
| Q3 25 | $120.6M | $66.0M | ||
| Q2 25 | $117.3M | $32.7M | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $101.9M | — | ||
| Q3 24 | $95.5M | — | ||
| Q2 24 | $89.6M | — | ||
| Q1 24 | $85.1M | — |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $26.0M | ||
| Q2 25 | $1.3M | $-4.7M | ||
| Q1 25 | $-47.7M | — | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | — | ||
| Q2 24 | $-40.5M | — | ||
| Q1 24 | $-35.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 81.3% | 33.5% | ||
| Q2 25 | 3.4% | -20.0% | ||
| Q1 25 | -41.3% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | -5.4% | — | ||
| Q2 24 | -40.7% | — | ||
| Q1 24 | -38.7% | — |
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | 39.4% | ||
| Q2 25 | 1.1% | -14.4% | ||
| Q1 25 | -43.2% | — | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | — | ||
| Q2 24 | -45.2% | — | ||
| Q1 24 | -42.0% | — |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $3.77 | $0.47 | ||
| Q2 25 | $0.05 | $-0.09 | ||
| Q1 25 | $-1.91 | — | ||
| Q4 24 | $1.81 | — | ||
| Q3 24 | $-0.34 | — | ||
| Q2 24 | $-1.64 | — | ||
| Q1 24 | $-1.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $436.1M | $494.8M |
| Total Assets | $1.9B | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | — | ||
| Q3 25 | $247.7M | $498.9M | ||
| Q2 25 | $198.9M | $286.8M | ||
| Q1 25 | $140.9M | — | ||
| Q4 24 | $197.6M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $175.9M | — | ||
| Q1 24 | $223.4M | — |
| Q4 25 | $436.1M | — | ||
| Q3 25 | $421.5M | $494.8M | ||
| Q2 25 | $332.5M | $240.1M | ||
| Q1 25 | $322.8M | — | ||
| Q4 24 | $362.1M | — | ||
| Q3 24 | $326.4M | — | ||
| Q2 24 | $322.6M | — | ||
| Q1 24 | $351.2M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $599.9M | ||
| Q2 25 | $1.7B | $332.3M | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $43.5M |
| Free Cash FlowOCF − Capex | $9.1M | $43.5M |
| FCF MarginFCF / Revenue | 7.6% | 65.8% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.53× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | — | ||
| Q3 25 | $16.9M | $43.5M | ||
| Q2 25 | $24.7M | $-12.6M | ||
| Q1 25 | $-35.6M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.8M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $17.7M | — |
| Q4 25 | $9.1M | — | ||
| Q3 25 | $16.8M | $43.5M | ||
| Q2 25 | $24.6M | $-12.6M | ||
| Q1 25 | $-35.7M | — | ||
| Q4 24 | $47.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $17.6M | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 13.9% | 65.8% | ||
| Q2 25 | 21.0% | -38.6% | ||
| Q1 25 | -32.4% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -11.9% | — | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | 1.67× | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
